Increased cannabinoid-1 (CB1) receptor activity can cause obesity and obesity-related T2DM; peripheral effects of CB1 antagonism are decreased bodyweight, improved glucose tolerance, increased adiponectin, and decreased insulin resistance. This evidence concerns the gene ADIPOQ and obesity due to melanocortin 4 receptor deficiency.